Provided By GlobeNewswire
Last update: Mar 27, 2025
WAYNE, Pa., March 27, 2025 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies, today announced that the preliminary results from its Ringer™ PBC IDE study were reported in a featured presentation at the CTO Plus Conference in New York by the study’s principal investigator, David E. Kandzari, MD, FACC, MSCAI, Chief, Piedmont Heart Institute and Cardiovascular Services, Chief Scientific Officer and Director, Interventional Cardiology at Piedmont Heart Institute, Atlanta, GA.*
Read more at globenewswire.comNYSE:TFX (4/21/2025, 3:56:08 PM)
128.74
-0.74 (-0.57%)
Find more stocks in the Stock Screener
TELEFLEX INC has a stellar value proposition. NYSE:TFX not only scores well in profitability, solvency, and liquidity but also maintains a very reasonable price point.